Aaron Rosenberg, Thomas Chalopin, Kushal Modi, Alison Bulkley, Kyla Finlayson, Corey Neff, Oliver Will, Yu-Hsuan Shih, Laurie Eliason, Thomas Marshall, Zander Pittman, Marc DeCongelio
{"title":"从多发性骨髓瘤(MM)患者和治疗医生的角度来看,无进展生存期(PFS)的价值:来自八个国家的定量研究结果","authors":"Aaron Rosenberg, Thomas Chalopin, Kushal Modi, Alison Bulkley, Kyla Finlayson, Corey Neff, Oliver Will, Yu-Hsuan Shih, Laurie Eliason, Thomas Marshall, Zander Pittman, Marc DeCongelio","doi":"10.1016/S2152-2650(25)03422-6","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 ","pages":"Pages S12-S13"},"PeriodicalIF":2.7000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Value of Progression-Free Survival (PFS) from the Perspectives of Patients with Multiple Myeloma (MM) and Treating Physicians: Quantitative Research Findings from Eight Countries\",\"authors\":\"Aaron Rosenberg, Thomas Chalopin, Kushal Modi, Alison Bulkley, Kyla Finlayson, Corey Neff, Oliver Will, Yu-Hsuan Shih, Laurie Eliason, Thomas Marshall, Zander Pittman, Marc DeCongelio\",\"doi\":\"10.1016/S2152-2650(25)03422-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":10348,\"journal\":{\"name\":\"Clinical Lymphoma, Myeloma & Leukemia\",\"volume\":\"25 \",\"pages\":\"Pages S12-S13\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Lymphoma, Myeloma & Leukemia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2152265025034226\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma, Myeloma & Leukemia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2152265025034226","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
The Value of Progression-Free Survival (PFS) from the Perspectives of Patients with Multiple Myeloma (MM) and Treating Physicians: Quantitative Research Findings from Eight Countries
期刊介绍:
Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.